MedTrace Logo

Safer Warfarin Treatment

NCT01042067 · Status: SUSPENDED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2011-04-27

No results posted yet for this study

Summary

The study is a national multicenter prospective observational study, including 200 patients. The main purpose of this study is to explore in more detail the influence of genetic variability (CYP enzymes and vitamin K dependent proteins) and dietary vitamin K status on warfarin dosing, clinical effect and adverse events with emphasis on the initial phase of treatment. The hypothesis is that genetic variability concerning CYP enzymes and vitamin K dependent proteins predict dosing and adverse events during warfarin treatment. The main aim is to individualize warfarin therapy and establish a treatment algorithm based on genotype and dietary vitamin K status to make the anticoagulation therapy with warfarin more secure.

Conditions

Interventions

OTHER

Blood specimens (whole blood, serum, plasma)

The patients follow standard warfarin treatment regimens and the only intervention is the sampling of blood specimens.

Sponsors & Collaborators

  • University of Oslo

    collaborator OTHER

  • Norwegian Medicines Agency

    collaborator OTHER_GOV

  • Norway: South-Eastern Norway Regional Health Authority

    collaborator UNKNOWN

  • Oslo University Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31

Countries

  • Norway

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01042067 on ClinicalTrials.gov